**Supplementary Data**

Additional details for *MET*-amplified patients with one or more postbaseline tumor assessment (n=9).

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table S2.** *MET*-amplified patients with ≥1 postbaseline tumor assessment (N=9) | | | | | | | | | |
| **Tumors: Figure 2B** | **1** | **2** | **3** | **4** | **5** | **6** | **7** | **8** | **9** |
| **Diagnosis** | Uterine | Gastro-esophageal | Colon | Colon | Renal | Ovarian | Gastric | Esophageal | Gastric |
| **Response** | Progressive disease | Progressive disease | Progressive disease | Stable disease | Stable disease | Partial response | Partial response | Partial response | Partial response |
| **No. of prior lines** | 7 | 2 | 4 | 6 | 4 | 7 | 4 | 2 | 2 |
| **Mean *MET/ CEP7* ratio** | 1.74 | NGSa | 6.4 | 1.29 | 2.43 | 1.76 | 6.91 | 7.81 | 2.5 |
| ***MET* amp cells, %** | 26 | NT | 92 | 27 | 54 | 21 | 100 | 99 | 41 |
| aConfirmed by NGS clinical assay.  NGS, next-generation sequencing; NT, not tested, no sample available. | | | | | | | | | |